About the Authors
- Xueqi Chen
-
Affiliations Department of Nuclear Medicine, Peking University First Hospital, Beijing, China, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
- Yun Zhou
-
* E-mail: yunzhou@jhmi.edu (YZ); rongfu_wang@163.com (RW)
Affiliations Department of Nuclear Medicine, Peking University First Hospital, Beijing, China, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
- Rongfu Wang
-
* E-mail: yunzhou@jhmi.edu (YZ); rongfu_wang@163.com (RW)
Affiliation Department of Nuclear Medicine, Peking University First Hospital, Beijing, China
- Haoyin Cao
-
Affiliation University Hospital, Hamburg-Eppendorf, Hamburg, Germany
- Savina Reid
-
Affiliation The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
- Rui Gao
-
Affiliations The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, Department of Nuclear Medicine, the First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China
- Dong Han
-
Affiliation Department of Computer Science and Engineering, Oakland University, Rochester, Michigan, United States of America
- Alzheimer’s Disease Neuroimaging Initiative
-
¶Membership of the Alzheimer’s Disease Neuroimaging Initiative is provided in the Acknowledgments.
Competing Interests
The authors have the following interests: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: Alzheimer’s Disease Neuroimaging Initiative (ADNI). Performed the experiments: Alzheimer’s Disease Neuroimaging Initiative (ADNI). Analyzed the data: XC YZ HC RG DH. Contributed reagents/materials/analysis tools: RW HC. Wrote the paper: XC YZ SR.